Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | DPP4 | P27487 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.75 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.75 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.75 |
| ▸ | GAPDH | P04406 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.75 |
| ▸ | STAT6 | P42226 | 1/20 | 0.75 |
| ▸ | PI4KA | P42356 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.75 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.75 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL12763613 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL2229394 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL18653532 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL2046912 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL20138477 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL15804 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL4110068 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL6748954 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL330178 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL29436140 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | claimed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | claimed |
| US-11542551-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-01-03 | — | — | US | claimed |
| US-20220186274-A1 | POLYNUCLEOTIDE MODIFICATION METHODS | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-06-16 | — | — | US | claimed |
| US-20200318179-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-10-08 | — | — | US | claimed |
| CN-106232834-B | Sample preparation method | 牛津纳米孔技术公司 | 2020-09-22 | — | — | CN | claimed |
| US-10669578-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-06-02 | — | — | US | claimed |
| CN-105705656-B | Method of producing a composite material | 牛津纳米孔技术公司 | 2020-02-21 | — | — | CN | claimed |
| EP-3033435-B1 | METHOD FOR FRAGMENTING NUCLEIC ACID BY MEANS OF TRANSPOSASE | OXFORD NANOPORE TECH LTD (GB) | 2019-07-24 | — | — | EP | claimed |
| WO-2015124935-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-08-27 | — | — | WO | claimed |
| EP-2895618-A1 | SAMPLE PREPARATION METHOD | Oxford Nanopore Technologies Limited (GB) | 2015-07-22 | — | — | EP | claimed |
| WO-2015022544-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-02-19 | — | — | WO | claimed |
| WO-2014108529-A1 | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-17 | — | — | WO | claimed |
| WO-2014041337-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-03-20 | — | — | WO | claimed |
| WO-2010056795-A1 | NOVEL SYNTHETIC DINUCLEOSIDE POLYPHOSPHATE ANALOGS AND THEIR USE AS NEW THERAPEUTIC AND/OR DIAGNOSTIC MODALITIES | ZATA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1262564-A2 | Dna sequencing by mass spectrometry | SEQUENOM, INC. (US) | 2002-12-04 | — | — | EP | claimed |
| US-6200747-B1 | AMPLIFYING NUCLEIC ACIDS BY POLYMERASE CHAIN REACTION; CALIBRATION | NORTH SHORE UNIVERSITY HOSPITAL RESEARCH CORP. | 2001-03-13 | — | — | US | claimed |
| US-5691141-A | SOLID PHASE SYNTHESIS, LINKING LARGE MOLECULES TO NUCLEOTIDES TO DIFFERENTIATE | SEQUENOM, INC. (US) | 1997-11-25 | — | — | US | claimed |
| US-5658764-A | METHOD FOR DETERMINING WHETHER AN INDIVIDUAL IS A CARRIER FOR OR AFFLICTED WITH A FRAGILE X MUTATION | NORTH SHORE UNIVERSITY HOSPITAL RESEARCH CORP. (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | SLC29A1 90/4885ADORA3 1197/4885MAPK1 3352/4885 |
| US-12630851-B2 | Polynucleotide modification methods | PNP, NT5C3B, UNG | SLC29A1 53/4885ADORA3 201/4885MAPK1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.